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Glaucoma, which affects more than 70 million people worldwide, is a heterogeneous
group of disorders with a resultant common denominator; optic neuropathy, eventually
leading to irreversible blindness. The clinical manifestations of primary open-angle
glaucoma (POAG), the most common subtype of glaucoma, include excavation of the
optic disc and progressive loss of visual field. Axonal degeneration of retinal ganglion
cells (RGCs) and apoptotic death of their cell bodies are observed in glaucoma, in which
the reduction of intraocular pressure (IOP) is known to slow progression of the disease.
A pattern of localized retinal nerve fiber layer (RNFL) defects in glaucoma patients indicates
that axonal degeneration may precede RGC body death in this condition. The mechanisms
of degeneration of neuronal cell bodies and their axons may differ. In this review, we
addressed the molecular mechanisms of cell body death and axonal degeneration in
glaucoma and proposed axonal protection in addition to cell body protection. The concept
of axonal protection may become a new therapeutic strategy to prevent further axonal
degeneration or revive dying axons in patients with preperimetric glaucoma. Further study
will be needed to clarify whether the combination therapy of axonal protection and cell
body protection will have greater protective effects in early or progressive glaucomatous
optic neuropathy (GON).
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INTRODUCTION
The axons of human retinal ganglion cells (RGCs) are approx-
imately 50mm in length and form synapses with cells in the
lateral geniculate nucleus of the thalamus. The axons are arranged
in bundles separated and ensheathed by glial cells. Upon exit-
ing through the lamina area, the axons become myelinated with
oligodendrocytes. Glaucomatous optic neuropathy (GON), the
second leading cause of blindness worldwide, is a neurodegenera-
tive disease characterized by structural damage to the optic nerve
and the slow progressive death of RGCs (Quigley, 1996; Resnikoff
et al., 2004). Previous reports indicated that GON initially occurs
in the lamina area and is associated with several factors, such as
disruption of neurotrophic factor, glial activation, and release of
tumor necrosis factor (TNF), oxidative stress, dysregulation of
the immune system, andmitochondrial dysfunction (Quigley and
Addicks, 1980; Tezel and Wax, 2000; Schori et al., 2001, Tezel,
2006; Ju et al., 2009). These changes contribute to deformation of
the lamina and subsequently activate several molecular pathways
to induce axonal degeneration and RGC body death. Therefore,
an understanding of the mechanism of axonal degeneration is
needed to develop new strategies for glaucoma treatment.
RGC bodies, which carry the final neuronal output of
the retina, receive visual signals from photoreceptors via the
two preceding layers of neuronal cells, bipolar and amacrine
cells, and transmit that information to the brain. Organelles
of RGCs, including the mitochondria, endoplasmic reticulum
(ER), Golgi, and cytoplasm, move from their sites of biogen-
esis in the cell body to distant axons and maintain the cel-
lular environment. The cell body controls cellular organelles,
and therefore cell body death influences their movements and
functions (DePina and Langford, 1999). Apoptosis is a major
category of cell body death signaling, and its characteristics
are nuclear fragmentation, chromatin condensation, DNA frag-
mentation, and cell shrinkage (Penfold and Provis, 1986; Smith
et al., 1989). Although most cell body death occurs follow-
ing axonal degeneration, the immune system, glial activation,
and oxidative stress also contribute to cell body death in the
retina independently axonal degeneration. Consequently, the
mechanism of cell body death due to GON must also be
elucidated.
The reduction of intraocular pressure (IOP) remains the main
strategy to slow the progression of glaucoma. However, thin-
ning of neurofibers and progression of visual field defects are
observed even in eyes in which IOP is reduced, suggesting that
disease progression is at least partially independent of IOP, espe-
cially in normal tension glaucoma (Harbin et al., 1976; Caprioli,
1997; Georgopoulos et al., 1997; Leske et al., 2003). Therefore,
the establishment of a neuroprotective strategy in GON is neces-
sary. Althoughmany papers focusing on cell body protection have
been published recently, there are few neuroprotective agents for
clinical application. Since the primary site of GON is the optic
nerve in the lamina, axonal protection has become an essential
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strategy for neuroprotective interventions, including secondary
cell body death.
In this review, we describe the molecular mechanisms of
axonal degeneration and cell body death in GON and discuss the
future prospects for neuroprotection.
CELL BODY INJURY
IOP ELEVATION AND RGC DEATH
Glaucoma is complex, multifactorial disease characterized by
axonal degeneration and RGC loss. The non-human primate
optic nerve shows close anatomic similarities to the human one,
with multiple layers of collagen and elastic tissue in the lamina
cribrosa (Anderson, 1969, 1970). While the non-primate, such
as rat and mouse, optic nerve head lacks that specific similar-
ity to the primate one, several other similarities are seen. Instead
of the lamina cribrosa, a lamina beam or glial lamina, of which
the astrocyte processes are in intimate contact with axons, occurs
in the lamina area (Morrison et al., 1995). Experimental primate
glaucoma indicates that IOP elevation itself may induce specific
changes in the composition of the optic nerve head extracellular
matrix (ECM) and obstruction by the lamina cribrosa in other-
wise normal eyes, including altered collagen and elastin fibrils and
deposition of several macromolecules within the pores, leading to
axonal degeneration and subsequent RGC death (Morrison et al.,
1990; Quigley et al., 1991a,b). In contrast, non-primate experi-
mental glaucoma models induces axonal degeneration without
banding of the lamina cribrosa, indicating that molecular changes
in the optic nerve are also essential factors in axonal degeneration
and RGC death.
RGC body death induced by high IOP also results in secondary
degeneration through several molecular changes. Interruption
of the retrograde axonal transport of neurotrophic factors has
been postulated as a mechanism of secondary RGC degenera-
tion (Quigley and Addicks, 1980). Furthermore, disruption of the
expression of the axonal motor protein dynein is observed in the
optic nerve head. Therefore, modulation of axonal transport is a
crucial event in GON (Martin et al., 2006).
IOP elevation induces oxidative stress in RGCs through
decreased activity of several enzymes comprising the antiox-
idant defense system, including superoxide dismutase (SOD),
glutathione peroxidase, and catalase, and has been implicated in
RGC body death (Moreno et al., 2004). Furthermore, we previ-
ously found that decreased thioredoxin 1 (Trx1) and thioredoxin
2 (Trx2) levels, which play critical roles in the regulation of oxida-
tive stress, are observed in the glaucomatous retina, and over-
expression of these proteins supports RGC survival (Munemasa
et al., 2008).
OXIDATIVE STRESS IN THE RETINA
Oxidative stress occurs when the generation of reactive oxy-
gen species (ROS) exceeds the cellular ability to neutralize and
eliminate them. ROS have been implicated as crucial factors in
neurodegenerative diseases, such as Alzheimer, Parkinson, and
Huntington diseases (Di Matteo and Esposito, 2003; Barber et al.,
2006; Browne and Beal, 2006; Savitt et al., 2006). ROS are gen-
erated predominantly in mitochondria through a variety of pro-
cesses such as normal aerobic metabolism and second messengers
in various signal transduction pathways. H2O2 is proposed as a
major contributor to oxidative damage by ROS after conversion
from superoxide released from mitochondria. Once generated,
H2O2 may further impair mitochondrial electron transport and
enhance ROS production. When H2O2 is present at high or
sustained levels, it induces severe damage not only to mitochon-
dria but also to cellular proteins, lipids, and nucleic acids, and
subsequently causes cell body death.
Retinal injury due to oxidative stress has been reported in
various animalmodels, including axotomy, ischemia-reperfusion,
N-methyl-D-aspartate (NMDA), and experimental glaucoma
(Kikuchi et al., 2000; Atlante et al., 2001; Tezel, 2006). Optic
nerve axotomy causes ROS production through glial activation,
disruption of trophic factors, and subsequent RGC death. Our
previous study showed that axotomy of the optic nerve causes a
change in redox status, indicating an increase in Trx1 and Trx2
levels in isolated RGCs. Overexpression of Trx1 and Trx2 pre-
vents axotomy-induced RGC loss, indicating the critical role of
the redox status in axotomized RGC degeneration (Munemasa
et al., 2006).
Tissue hypoxia is also associated with RGC degeneration
through oxidative injury. Hypoxia-inducible factor-1 alpha (HIF-
1α), an O2-regulated transcriptional activator, has been identified
as a key modulator of O2 homeostasis. Upregulation of HIF-1α
mRNA is observed in RGC-5 cells under H2O2-induced oxida-
tive stress (Chen et al., 2012). HIF-1α under hypoxia induces the
expression of various transcription factors including those encod-
ing erythropoietin, glucose transporters, glycolytic enzymes, vas-
cular endothelial growth factor, inducible nitric oxide synthase
(NOS), and heme oxygenase 1, and their protein products
increase the delivery of or facilitate metabolic adaptation to
hypoxia (Wang et al., 1995; Iyer et al., 1998). The early increase
in the expression of HIF-1α is accompanied by prosurvival fac-
tors, such as heat-shock protein (Hsp)27 and 72. On the contrary,
proapoptotic molecules including p53 and caspase are observed
in the retina under long-term hypoxic conditioning (Tezel and
Wax, 1999; Wax et al., 2008). Thus, while the early increase in
HIF-1α is accompanied by the activation of adaptive prosurvival
factors, long-term exposure to hypoxia induces the activation of
proapoptotic signaling. The expression of HIF-1α during RGC
degeneration ismore evident in human glaucomatous donor eyes,
supporting the occurrence of sustained tissue hypoxia in glau-
coma. HIF-1α immunoreacitivity is observed not only in the optic
nerve but also in the retina in glaucoma (Tezel and Wax, 2004).
These observations indicate that hypoxic stress in glaucoma is the
initial stress, followed by secondary degeneration.
It has been reported that RGCs are vulnerable to oxida-
tive stress, especially to SOD1 knockout (Yuki et al., 2011). An
increase in ROS is observed in the RGCs of SOD1-deficient
mice. Furthermore, RGC degeneration precedes the degener-
ation of other layers in SOD1-deficient mice, indicating the
greater vulnerability of RGCs to oxidative stress compared with
other neurons. RGC death following axotomy of the optic
nerve is due to the bursting of RGC bodies by intracellu-
lar superoxide (Kanamori et al., 2010). ROS accumulation in
response to axotomy of the optic nerve induces RGC degener-
ation through changes in the mitochondrial electron transport
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chain (Lieven et al., 2006). Mitochondrial dysfunction has been
also reported in RGC body death in oxidative stress. TNF and
buthionine sulfoximine (BSO), an inducer of oxidative stress,
cause increased mitochondrial membrane permeability, with a
concomitant decrease in Trx2 levels, and subsequently transloca-
tion of the apoptosis-inducing factor (AIF) from mitochondrial
inner membrane space to the nuclei of RGC-5 cells. Inhibition
of mitochondrial permeability by Trx2 overexpression prevents
the cytotoxic effects induced by oxidative stress (Munemasa et al.,
2009). Thus, mitochondria are one of the target organelles of
oxidative injury, and modulation of mitochondria may become
a strategy to reduce oxidative stress.
AUTOIMMUNE REGULATION AND RGC DEATH
Ocular immune privilege regulates immune responses, thereby
controlling potentially damaging and sight-threatening autoim-
mune disease (Gregerson, 1998; Streilein et al., 2000). In the
central nervous system (CNS), activated T cells were shown to
migrate to the site of injury, suggesting that homing T cells that
encounter their related antigens at the lesion site and contribute
to lesion repair. Apoptotic elimination of T cells is an essential
protective mechanism to prevent inflammation and antigen con-
tact in the eye through naturally occurring CD4+ CD25+ regula-
tory T cells (Treg) (Peitsch et al., 1993; Kipnis et al., 2002). CD4+
activation requires an interaction between the antigen-restricted
T cell receptor of the T cell and major histocompatibility complex
class 2, an antigen present on the surface of antigen-presenting
cells, such as B cells, macrophages, microglia, and dendritic cells
(Bretscher, 1992). The accumulation of T cells that migrate to
injured tissue likely contributes to the endogenous protective
mechanism, but their activity is not sufficient to have a percep-
tible effect. Therefore, it may be necessary to increase the number
of migrating T cells to prevent neurodegeneration. Regulation
of autoimmune T cells reactive to myelin antigens can preserve
the organism following neuronal injuries (Hauben et al., 2000).
Furthermore, T cells specific for copaxone 1, a compound used
in the treatment of multiple sclerosis, inhibit RGC loss after optic
nerve crush (Kipnis et al., 2002). However, once T cells are pre-
sented with myelin antigen, they can also initiate an immune
response leading to neurodegeneration. Therefore, modulation of
the autoimmune response may be important to develop a new
strategy for neuroprotection.
GLIAL CELL ACTIVATION AND RGC DEATH
Glial cell activation occurs in neurodegeneration through vari-
ous molecular changes. Gliosis is characterized as the prolifer-
ation and hypertrophy of glial cells and results in upregulation
of intermediate filaments, such as glial fibrillary acidic protein
(GFAP), vimentine, and nestin, and thickening of large cells.
Upregulation of the intermediate filaments places them in contact
with cytoskeletal components and the ECM, enabling them to ini-
tiate rapid cytoskeletal remodeling and exert long-term effects on
tissue structure. In the retina, there is an additional glial cell type,
the Müller cell, which is a specialized radial glial cell that spans
the entire thickness of the retina (Laties and Nichols, 1971) and
connects all retinal neuronal somata and processes. In the healthy
retina, Müller cells contribute to maintaining the retinal structure
and functions, such as glucose metabolism (Poitry-Yamate et al.,
1995), ion maintenance (Tsacopoulos and Magistretti, 1996),
regulation of retinal blood flow (Paulson and Newman, 1987),
uptake and recycling of neurotransmitters (Matsui et al., 1999),
and release of various factors. Although retinal neurons are highly
susceptible to various forms of injury including ischemia and high
IOP, Müller cells are strikingly resistant to stress. Müller cell glio-
sis in response to various stresses, such as ischemia-reperfusion
(Pannicke et al., 2005), axotomy of the optic nerve (Chun et al.,
2000), excessive glutamate (Honjo et al., 2000; Kawasaki et al.,
2000), and ocular hypertension (Carter-Dawson et al., 1998), has
an endogenous protective function. The mechanism by which
acute activation of Müller cells is neuroprotective after injury is
due to the release of neurotrophic factors, such as brain-derived
neurotrophic factor (BDNF), ciliary-derived neurotrophic fac-
tor, and pigment epithelium-derived factor, and their antioxidant
function (Ju et al., 1999; Oku et al., 2002; Sato et al., 2008;
Unterlauft et al., 2012). Conversely, chronic activation of the
Müller glia is recognized as an indicator of ongoing neuroin-
flammation in retinal neurodegeneration. TNF-α and interleukin
(IL)-1β, which are major cytokines produced by activated glial
cells, are linked to inflammatory processes and mediate RGC
death through several pathways, including nerve factor (NF)-κB
activation, autophagy regulation, nitric oxide (NO) synthesis, and
inflammasome assembly (Tezel and Wax, 2000; Kitaoka et al.,
2007; Tezel et al., 2012). Furthermore, NOS 2, which is expressed
in the presence of cytokines, is synthesized in activated Müller
cells. NO produced in high concentrations by the inducible iso-
form expressed in activated Müller cells can be neurotoxic to the
cells. Thus, activated Müller cells have dual functions depending
on the time course after injury.
When exposed to inflammatory stimuli, RGCs enter an active
regenerative state, which helps their neurons to survive injury and
regenerate lengthy axons through the injured optic nerve (Fischer
et al., 2001; Yin et al., 2003). Intravitreal injection of Pam3 Cys,
a TLR2 agonist, induces the upregulation of ciliary neurotrophic
factor and GFAP expression in the glia, accompanied by the
activation of the JAK/STAT3 pathway in RGCs. Consequently,
RGCs are converted to the regenerative state, indicated by sig-
nificant upregulation of GAP43 expression and increased neurite
outgrowth of RGCs in culture (Hauk et al., 2010).
Müller cells undergo a proliferative response after neurotoxic
injury by re-entering the cell cycle. Many of these cells begin to
lose their Müller glial phenotype and express a neurofilament
transcription factor common to retinal progenitor cells, such as
Pax6, Chx10, and CASH-1, indicating Müller cell dedifferentia-
tion into retinal progenitors and subsequent formation of new
retinal neurons (Fischer and Reh, 2001). These observations sug-
gest that Müller cells may play a role in neural regeneration in
response to neural injury.
ER STRESS AND RGC INJURY
The ER is an important subcellular organelle responsible for the
proper folding and sorting of proteins. Only properly folded pro-
teins can be transported to the Golgi body for further processing.
In addition, the ER also serves as a dynamic pool of Ca2+, gov-
erning intracellular Ca2+ homeostasis (Görlach et al., 2006). It is
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susceptible to various stresses that provoke the accumulation
of unfolded proteins in the ER lumen. Three ER-related pro-
teins, inositol-requiring enzyme-1, activating transcription factor
6, and protein kinase RNA (PKR)-like ER kinase (PERK), are
involved in the initial signaling to the cell through the unfolded
protein response.
Previous studies found that increased ER stress in response
to ischemia-reperfusion, tunicamycin, the commom ER stress
inducer NMDA, and IOP elevation induces apoptotic RGC
degeneration accompanied by increased ER stress-related pro-
teins, such as Bip, PERK, and CHOP (Shimazawa et al., 2007;
Inokuchi et al., 2009; Doh et al., 2010). Intravitreal injection of
tunicamycin results in RGC loss and reduced thickness of the
inner retina. Pharmaceutical induction of Bip, an ER chaperone
that facilitates protein folding and reduces ER stress, attenuates
the retinal expression of CHOP and activation of the apoptotic
cascade and inhibits apoptotic RGC death (Inokuchi et al., 2009).
Furthermore, CHOP knockout mice show resistance to NMDA-
induced retinal injury (Awai et al., 2006). Thus, ER stress plays
a pivotal role in retinal neuronal degeneration, and modulation
of its activity may become a new strategy for neuroprotection
against retinal injury.
EXCITOTOXICITY
Glutamate, a major excitatory neurotransmitter, is implicated
in several ocular diseases, including optic neuropathy and
diabetic retinopathy. Glutamate receptors are classified as metab
otropic and ionotropic types, the latter of which are further sub-
categorized into NMDA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, and kainate
receptors. These receptors are encoded by at least six gene
families: a single family for AMPA receptors (GluR1, 2, 3, 4);
two for kinate (GluR5, 6, 7 and KA 1, 2); and three for NMDA
(NR1, NR2A, B, C, D, and NR3A, B) (Dingledine et al., 1999).
Glutamate neurotoxicity has been predominantly linked to
excessive stimulation of NMDA receptors, which are activated by
coagonist NMDA (glutamate) and glycine. Stimulation of NMDA
receptors is observed in the retina in various animal models of
neurodegeneration, such as experimental glaucoma, axotomy,
ischemia-reperfusion, and NMDA injection (Lam et al., 1997,
1999; Kikuchi et al., 2000; Dong et al., 2008). Intravitreal injection
of NMDA causes relatively acute neuronal death, especially in the
inner retina, through several molecular pathways. The increase
in intracellular Ca2+ influx is the initial key molecular event
in NMDA receptor-mediated cell death (Laabich et al., 2001).
Intracellular Ca2+ overload activates Ca2+-dependent enzyme
systems such as calpain and calcium/calmodulin-dependent
kinase 2 (CaMK) (Chiu et al., 2005; Takeda et al., 2007). Calpain
is localized in TUNEL-positive apoptotic cells in the inner retina
after NMDA injection, and inhibition of calpain resulted in less
NMDA-induced neuronal cell death, suggesting a proapoptotic
role of calpain in NMDA-induced neutrotoxicity. In contrast,
phosphorylation of CaMK2 is observed in the retina relatively
early after NMDA injection, and inhibition of CaMK2 synthesis
accelerates NMDA-induced RGC loss, indicating an antiapoptotic
role of CaMK2 (Takeda et al., 2007). Intracellular Ca2+ influx also
affects mitochondrial activity, such as the release of cytochrome
C and ROS, and results in the activation of several apoptotic
pathways. Our previous studies on the downstream intracellular
Ca2+ influx led us to propose that the activation of proapoptotic
molecules, such as NF-κB p65 and p38, c-Jun N-terminal kinase
(JNK), and c-Jun, plays a role in NMDA-induced neurotoxicity
(Kitaoka et al., 2004; Munemasa et al., 2005, 2006; Takada
et al., 2011). An inflammatory response, i.e., the upregulation
of IL-1β, is also observed in the glia and RGCs after NMDA
administration, suggesting the involvement of inflammation in
response to excitotoxicity. Thus, although NMDA penetrates
into the inner retina after intravitreal injection and induces
various molecular changes in the glia and RGCs which lead to
RGC apoptotic degeneration and inner retinal thinning, those
changes may also affect optic nerve degeneration. Our previous
study showed that axonal degeneration with neurofilament loss is
evident 3 days after intravitreal injection of NMDA (Kuribayashi
et al., 2010). These changes occur after TUNEL-positive DNA
fragmentation in RGCs, indicating anterograde degenerative
change in NMDA-induced neurotoxicity. Furthermore, apoptotic
cell body death affects axonal transport to axons through the
disruption of kinesin-1 (KIF5b) activity, an anterograde axonal
motor protein related to microtubules and neurofilament.
These findings indicate anterograde neurodegeneration in
NMDA-induced neurotoxicity (Kuribayashi et al., 2010).
Glutamate was implicated to have a role in GON in an in vivo
experimental glaucoma model (Kim et al., 2007, Neuroscience;
Luo et al., 2009, Cell. Mol. Neurobiol.). IOP elevation causes stim-
ulation of NMDA receptors in RGC bodies. Excessive levels of
NMDA receptors cause apoptotic RGC death and subsequent
axonal degeneration. Although themechanism bywhich the stim-
ulation of NMDA receptors occurs in high IOP-induced RGC
death has not been fully elucidated, the inhibition of NMDA
receptors may be important to prevent secondary degeneration
in the optic nerve.
The elimination of excessive glutamate in the retina and vit-
reous is also important in slowing retinal neurodegenerative
disease. The glutamate transporter is the only mechanism for the
removal of glutamate from the extracellular fluid in the retina
(Danbolt, 2001). Increased glutamate levels may result from a fail-
ure of glutamate transporters adjacent to RGCs. Mice deficient
in the glutamate/aspartate transporter (GLAST) and excitatory
amino acid carrier 1, which are glutamate transporters, demon-
strate spontaneous RGC death, and optic nerve degeneration
without IOP elevation, suggesting that glutamate transporters are
necessary to prevent excitotoxic retinal damage (Harada et al.,
1998, 2007; Sarthy et al., 2005). GLAST immunoreactivity is
present throughout the retina and can be double-labeledwith glu-
tamine synthetase, a specific marker of Müller glial cells. These
observations indicate that the intracellular glutamate concentra-
tion is dependent on glutamate uptake via GLAST in Müller
glial cells.
ENDOTHELIN IN RGC DEATH
Endothelin (ET)-1 is a well-known, potent, long-acting vaso-
constrictor peptide in the CNS which reduces blood flow in the
retina. There are two distinct G-protein-coupled receptors, the
ET A receptor (ETAR) and ET B receptor (ETBR) that mediate
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the biological effects of ET. These receptors are abundantly
expressed in various ocular tissues (MacCumber and D’Anna,
1994; Chauhan, 2008). ETAR is predominantly located in the
retinal vessels and choroid vessels, and its activation sustains vaso-
constriction of vascular smooth muscle cells. In contrast, ETBR is
detected in neuronal cells and glial cells in the retina and optic
nerve, where it causes the release of NO and results in transient
vasodilation.
Activation of ET receptors was proposed as a mechanism of
neuronal degeneration in the retina via ischemia and apoptotic
cell death (Lau et al., 2006). Retrobulbar delivery of ET-1 can
induce selective RGC degeneration, whereas intravitreal injec-
tion of ET-1 causes neuronal death not only of RGCs but also
of other neurons. Since the mechanism by which ET-1 induces
neuronal degeneration is mainly vasoconstriction, activated glia
may also contribute. Our previous study showed that intravit-
real injection of ET-1 induces phosphorylation of extracellular
signal-regulated kinase in GFAP-positive glial cells. Furthermore,
ET-1 induces matrix metalloproteinase (MMP)-2 and tissue
inhibitors of matrix metalloproteinases (TIMPs)-1 and -2 as well
as ECM protein expression, including fibronectin, in astrocytes
(He et al., 2007). These observations implicate the relationship
of MMP-2, TIMPs, and changes in the optic nerve head, includ-
ing ECM remodeling, in ET-1-induced astrogliosis. In contrast,
ET-1 increases intracellular NO, superoxide, and peroxynitrite
in cultured retinal neurons. Furthermore, ET-1 causes increases
in MMP-9 expression in RGCs and subsequently apoptotic RGC
death (Aktas et al., 2010). Thus, ET signaling pathways exist not
only in glial cells, such as astrocytes of the optic nerve head and
Müller cells, but also in retinal neurons.
Several types of stress promote the activation of ET recep-
tors in the optic nerve head and retina, with subsequent axonal
degeneration and RGC death. Optic nerve crush promotes the
expression of ETRA and ETRB in the optic nerve. Inhibition of
ETRB by BQ-788 preserves RGCs, most likely by attenuating neu-
roinflammatory events, indicating RGCdegeneration through the
activation of ETRB (Tonari et al., 2012). Furthermore, IOP pro-
duces increased expression of ETRB in the retina, mainly RGCs;
the nerve fiber layer (NFL); inner plexiform layer; and inner
nuclear layer. RGC loss induced by high IOP is attenuated in
ETRB-deficient (knockout) rats (Minton et al., 2012). These find-
ings raise the possibility that ETRB contributes to glaucomatous
RGC body death.
RGC DEATH IN AGING
Age is a well-recognized risk factor for the development of glau-
coma. The prevalence of glaucoma in Caucasians in their 70 s
can be 3.5–5-fold greater than that in their 40 s (Tielsch et al.,
1991). However, the reason for this association with age has
not been thoroughly elucidated. It is possible that older eyes
are less resistant to elevated IOP. Age was found to be predic-
tive of open-angle glaucoma development in patients with ocular
hypertension (Gordon et al., 2002).
Many visual abilities decline with age as a result of the nor-
mal, non-pathologic loss of neurons in the peripheral and cen-
tral visual pathways (Spear, 1993; Neufeld and Gachie, 2003).
The age-related losses of neurons in the inner retina have been
well documented. A decline in the number of neuronal cells is
observed not only for RGCs, but also for interneurons in the INL
and photoreceptors in the outer nuclear layer. The effect of aging
has been investigated by both morphological analysis of RGC
bodies and their axons in the optic nerve and by optical measure-
ment of the retinal nerve fiber layer (RNFL) (Repka and Quigley,
1989; Harman et al., 2000). Investigations of the number of axons
in the optic nerve found systemic age-related losses at rates rang-
ing from 0.3 to 0.6% per year, whereas the age-related thinning of
the RNFL occurs at a somewhat lower rate of 0.2% per year. The
differences in age-related losses in RGCs and RNFL thickness sug-
gest that axons do not represent a constant proportion of the total
NFL thickness as shown by optical coherence tomography mea-
surements. However, evidence for age-related variations in axon
density in the RNFL requires quantitative modeling of RGCs and
RNFL axons as a function of age.
Visual function also clearly declines with age. The majority
of apparently disease-free individuals experience some degree of
age-associated decline in vision (Spear, 1993). However, at least
some age-related changes, including reductions in visual acu-
ity, spatial contrast sensitivity, and motion sensitivity, cannot be
attributed to optical changes. These defects are therefore likely to
reflect changes in neurons, including those of the retina.
SECONDARY DEGENERATION OF RGCs
The secondary degeneration of neighboring neurons is due to
changes in surrounding biochemical events. A variety of mech-
anisms of secondary degeneration have been proposed, such as
alteration of extracellular ion concentration, release of oxygen
free radicals, and high levels of excitatory neurotransmitters (Liu
and McAdoo, 1993; Dusart and Schwab, 1994; Faden, 1996). The
experimental rat or mouse glaucoma model using IOP elevation
may not be suitable for investigating secondary RGC degen-
eration, because rats and mice lack the lamina cribrosa, and
therefore all RGCs axons are presumably exposed to the primary
insult without banding of the lamina cribrosa (Morrison et al.,
1995). In contrast, glaucoma patients exhibit pore banding in
the lamina cribrosa, which results in partial axonal degenera-
tion and fan-shaped RNFL thinning. RNFL thinning is commonly
observed when glaucoma isrelatively advanced. At that time,
there is still an opportunity to prevent further secondary RGC
injury.
CELL BODY PROTECTION
ANTIOXIDANTS
It has been suggested that antioxidant systems, which remove
free radicals and inhibit the production and release of ROS, are
activated when superoxide and NO are abundantly observed in
cells. A decrease in free radicals protects cellular and subcellular
integrity under hypoxic conditions. In addition, suppression of
free radical-mediated lipid peroxidation directly interferes with
the early phase of apoptotic cell death. The lipid peroxidation
inhibitor tirilazad mesylate partially prevents RGC death induced
by the absence of neurotrophins in mixed culture. Furthermore,
the flavonoids baicalin and genistein also attenuate rotetone-
induced oxidative stress through the inhibition of lipid peroxi-
dation (Kamalden et al., 2012).
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Overexpression of redox proteins, such as Trx1 and Trx2, in
RGC-5 cells contributes to cell survival against glutamate/BSO-
induced cytotoxicity (Munemasa et al., 2008). It has been
assumed that Trx1 inhibits the downstream release of ASK1 from
the Trx1/ASK1 complex in the cytosol, resulting in the inhibi-
tion of the JNK and p38 apoptotic pathway (Nadeau et al., 2007).
Trx2 regulates mitochondria without membrane permeabiliza-
tion and apoptosis via a redox-active site cysteine-independent
mechanism, including inhibition of release of cytochrome C
(Wang et al., 2006). Modulation of the redox status may there-
fore become an additional strategy for cytoprotection against
apoptotic RGC body death.
GENE THERAPY
Electroporation can introduce large molecules such as DNA
into cells. Recently, we have modified a previous method and
succeeded in gene delivery to RGCs with greater than 40%
transfection efficiency (Munemasa et al., 2008). Overexpression
of Trx1 and Trx2 with electroporation after intravitreal injec-
tion of these plasmid DNAs contribute to cell survival in
ocular hypertension and after optic nerve transection-induced
RGC body death. In addition, Trx2 overexpression with elec-
troporation was confirmed using immunoblotting not only
in the retina but also in the optic nerve, indicating suc-
cessful gene delivery to the optic nerve. Our recent work
has shown that overxpression of Nell2, a neuron-specific
thrombospondin-1-like extracellular protein, also preserves axo-
tomized RGCs through MACF1 interaction (Munemasa et al.,
2012). Although gene delivery to RGCs by electroporation
can reduce the impact of various forms of stress, the clini-
cal application of this strategy is limited by the efficiency of
transfection.
Adenoviral vectors are effective in reducing functional dam-
age in several models of ocular disease (Ali et al., 2000;
Acland et al., 2001). Viruses were selected during evolution to
enter cells cleanly and efficiently. BDNF-expressing modified
adeno-associated virus (AAV) temporarily delays RGC degen-
eration after IOP elevation, with long-term transgene effects
(Martin et al., 2002). A recent study has shown that the intra-
muscular injection of systemic AAV carrying erythropoietin
(rAAV2/5. CMV.EpoR76) protects against RGC body death and
axonal degeneration in DBA/2J glaucomatous mice. In addition,
the systemically administered mutated gene can reduce the toxic
side effects of AAV (Sullivan et al., 2011). Thus, inserting a neu-
roprotective candidate into AAV and systemic administration or
intravitreal injection may become a potential adjunctive therapy
to prevent RGC body death.
AXONAL INJURY
LAMINAR AND BDNF
It has been suggested that oligodendrocyte loss leads to a loss
of axons in a hypertensive glaucoma model (Nakazawa et al.,
2006). On the other hand, astrocytes play crucial roles in the early
stage of axon loss, whereas oligodendrocyte loss occurs after axons
have already degenerated in hypertensive glaucoma (Son et al.,
2010). Among oligodendrocytes, astrocytes, and microglia, the
loss of BDNF may specifically affect the oligodendrocyte lineage
cell population, and BDNF may be a critical factor in the devel-
opment of oligodendrocytes and the recovery of oligodendrocytes
from a demyelinating lesion (VonDran et al., 2011). It was shown
that the axon diameter and proportion of myelinated axons were
reduced in the optic nerve in mice lacking BDNF (Cellerino
et al., 1997). An increase in astrocyte number was observed in
the optic nerve in the mouse glaucoma model, indicating that
astrocytes were activated, thereby leading to demyelination in
association with the process of axon loss (Mabuchi et al., 2003).
On the other hand, previous studies demonstrated that the acti-
vation of microglia contributes to axon damage in glaucoma
(Yuan and Neufeld, 2001). Optic nerve degeneration was par-
alleled by a loss of axons and an increase in microglia in the
DBA/2NNia mouse (May and Mittag, 2006). However, to the
best of our kowledge, there is no report showing that the acti-
vation of oligodendrocytes leads to axonal damage in glaucoma.
These findings have been implicated that the activation of astro-
cytes and microglia and decrease in oligodendrocytes may be
associated with axonal damage. Endogenous BDNF is present
predominantly in myelin rather than in the axoplasm in the
myelinated optic nerve axon (Fujino et al., 2009). Previous stud-
ies demonstrated that endogenous BDNF is transported from
synapses to RGC bodies, thereby contributing to RGC survival
(DiStefano et al., 1992; Quigley et al., 2000). Obstruction of
BDNF axonal transport has been reported in the unmyelinated
optic nerve in a hypertensive glaucomamodel (Pease et al., 2000).
In the normal spinal cord, most oligodendrocytes exhibit BDNF
immunoreactivity (Dougherty et al., 2000). In the basal fore-
brain, oligodendrocytes were shown to provide BDNF to nearby
neurons (Dai et al., 2003). Release of BDNF from oligodendro-
cytes is regulated through metabotrophic glutamate receptors,
and cortical oligodendrocytes also provide trophic support to
neurons (Bagayogo and Dreyfus, 2009). Myelin containing BDNF
terminates at the laminar portion between the myelinated and
unmyelinated areas in the optic nerve. This may be involved in
the disruption of BDNF axonal transport at the laminar portion
under certain conditions. Thus, not only mechanical obstruction,
such the relationship between myelin and axons at the laminar
portion, may be one causative factor of glaucomatous damage
starting at the laminar portion.
MITOCHONDRIA AND AXONAL DEGENERATION
Optic atrophy type 1 (Opa1) is a component of the mitochon-
drial network and plays a role in the regulation of mitochon-
dria in RGC pathophysiology (Delettre et al., 2000). Although
Opa1 does not promote mitochondrial docking, it may affect
the fusion step to regulate mitochondrial morphology (Cipolat
et al., 2004). A recent study has demonstrated an increased
synaptic vesicle number in bipolar cell terminal arbors with-
out significant loss of mitochondrial membrane potential in
the retina and optic nerve, suggesting that Opa1 may be an
essential factor in RGC synaptic architecture and connectivity
(Williams et al., 2012). Compensation of oxidative phosphory-
lation function may be important for maintaining ATP synthesis
in early stage OPA1-related optic neuropathy (Van Bergen et al.,
2011). A recent meta-analysis study has shown an association
between OPA1 polymorphisms and the risk for normal tension
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glaucoma in Caucasians but not in Asians (Guo et al., 2012).
That study also found no difference in the association between
OPA1 polymorphisms and hypertensive glaucoma in Asians and
Caucasians (Guo et al., 2012). An investigation using human lam-
ina cribrosa cells study which obtained from donors with no his-
tory of glaucoma and from donors with glaucoma demonstrated
increased ROS production, compromised antioxidant capacity,
mitochondrial dysfunction, and dysfunctional Ca2+ homeosta-
sis in glaucomatous lamina cribrosa cells compared with normal
lamina cribrosa cells and found that the capacity of glaucomatous
lamina cribrosa cells to inhibit the increase in ROS production
appeared to be impaired (McElnea et al., 2011). Therefore, mito-
chondrial dysfunction in lamina cribrosa cells may be involved in
glaucoma pathophysiology (McElnea et al., 2011). OPA1 expres-
sion and the OPA1/β-globulin ratio were both significantly lower
in primary open-angle glaucoma (POAG) patients than in con-
trols, suggesting that decreased OPA1 expression in those patients
may contribute to RGC apoptosis as one primary mechanism
of optic nerve damage (Bosley et al., 2011). The concentration
of mitochondria in unmyelinated axons is much higher than
that in myelinated axons in the optic nerve (Perge et al., 2009).
An increase in mitochondrial OPA1 has been suggested to be
an important cellular defense mechanism against hypertensive-
mediated RGC damage (Dai et al., 2011), and such an endogenous
defense response can be seen in the cell bodies. In addition,
mitochondrial matrix swelling and cristae volume depletion were
reported in the unmyelinated optic nerve head of glaucomatous
DBA/2J mice (Ju et al., 2008). The number of Mitotracker-labeled
mitochondria decreased in the unmyelinated optic nerve portion
in a hypertensive glaucomamodel (Munemasa et al., 2010). Thus,
not only mitochondrial dysfunction in lamina cribrosa cells but
also in the axons at the laminar portion may also be one causative
factor of glaucomatous optic nerve damage.
TNF AND AXONAL DEGENERATION
TNF has been linked to optic nerve degeneration in glaucoma
patients (Yan et al., 2000; Yuan and Neufeld, 2000; Tezel et al.,
2001). TNF release by glial cells was induced on exposure to sim-
ulated ischemia and elevated hydrostatic pressure, resulting in
apoptotic RGC death (Tezel and Wax, 2000). A recent study has
shown that a significantly higher percentage of patients in the
glaucoma group were positive for TNF in the aqueous humor
compared with the cataract group (Sawada et al., 2010). More
recently, a study of proteomic data from human glaucoma has
shown a prominent upregulation of TNF/TNF receptor 1 sig-
naling in the glaucomatous retina (Yang et al., 2011). It was
reported that a significant elevation of endogenous TNF occurs
in the retina in a hypertensive glaucomamouse model (Nakazawa
et al., 2006). In addition, a significant increase in TNF levels
was observed in the optic nerve in a hypertensive glaucoma rat
model (Munemasa et al., 2010). Exogenous TNF was shown to
cause primary optic nerve axonal degeneration with subsequent
slow RGC body death (Kitaoka et al., 2006; Nakazawa et al.,
2006). Microglial activation and upregulation of nuclear factor-
κB p65 may be involved in this process (Kitaoka et al., 2006).
Taken together, the results indicate that TNF released from glial
cells may play a pivotal role in axonal degeneration in glaucoma.
This finding is supported by a more recent study showing that
etanercept, a TNF blocker, exerted axonal protection in a rat
hypertensive glaucoma model (Roh et al., 2012).
AXONAL PROTECTION
BDNF AND AXONAL PROTECTION
A recent study has demonstrated that transplantation of BDNF-
secreting mesenchymal stem cells exerts optic nerve protection
in a hypertensive glaucoma rat model (Harper et al., 2011). It
was reported that intravitreal injection of BDNF significantly
prevented axonal loss after optic nerve crush in cats, and the
injection combined with delivery of BDNF to the visual cortex
exerted greater protection (Weber et al., 2010). BDNF can induce
phosphorylation of the cAMP response element-binding (CREB)
protein in certain neurons (Finkbeiner et al., 1997; Watson et al.,
1999). Several reports suggested a prosurvival role of the CREB
protein in the CNS (Walton et al., 1999; Lonze and Ginty, 2002).
The expression of constitutively active CREB protein is suffi-
cient to promote regeneration of dorsal root ganglion axons (Gao
et al., 2004). Since CREB-binding sequences have been identified
in the BDNF gene (Tao et al., 1998), BDNF can be upregu-
lated by CREB (Bonni et al., 1999; Freeland et al., 2001), and
therefore the CREB may be located both upstream and down-
stream of BDNF. We previously demonstrated that intravitreal
injection of BDNF can upregulate the p-CREB protein level in
nuclei in oligodendrocytes, with subsequent regulation of BDNF
expression in the optic nerve, leading to axonal protection against
TNF-induced optic nerve degeneration (Fujino et al., 2009). Since
it was demonstrated that BDNF is produced by oligodendro-
cytes and can provide local trophic support for nearby neurons
in the basal forebrain (Dai et al., 2003), it is possible that BDNF
in oligodendrocytes may serve as a protective moderator for
optic nerve axons. It is interesting to note that brimonidine,
which can potentially upregulate BDNF (Gao et al., 2002), pre-
served optic nerve axons in a hypertensive rat glaucoma model
(Lambert et al., 2011). Moreover, the compound bis(3-propionic
acid methyl ester)phenylphosphine borane reducing complex 1
exhibits axonal protection in the optic nerve in a hypertensive
glaucoma rat model with increasing BDNF levels (Almasieh et al.,
2011). Thus, BDNF may have beneficial effects on not only on
RGC bodies but also on their axons in glaucoma.
NICOTINAMIDE ADENINE DINUCLEOTIDE AND AXONAL PROTECTION
Nicotinamide adenine dinucleotide (NAD), a key intermediate
in cellular energy homeostasis, has been suggested to play cru-
cial roles in axonal degeneration in cultured neurons. SIRT1 is
a member of a highly conserved gene family (sirtuins) encod-
ing NAD+-dependent deacetylases (North and Verdin, 2004).
SIRT1 activation or exogenous NAD supply may prevent axonal
degradation in dorsal root ganglia explant cultures (Araki et al.,
2004). Previous studies demonstrated a decline in NAD lev-
els in the transected wallerian degenerating axons of dorsal
root ganglia (Wang et al., 2005) and a decline in NAD lev-
els in the cervical spinal cords of an experimental autoim-
mune encephalomyelitis model (Kaneko et al., 2006), suggesting
that decreased NAD may be involved in axonal degeneration.
Our previous study also showed a decrease in NAD levels in
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the optic nerve in a TNF-induced axonal degeneration model
and that the exogenous NAD supply can exert axonal pro-
tection in the optic nerve (Kitaoka et al., 2009). In addition,
axonal density in optic nerves, 14 and 30 days postimmuniza-
tion demonstrated that the administration of oral SRT501, a
SIRT1 activator, prevented the loss of axons found in experi-
mental autoimmune encephalomyelitis-related optic neuritis eyes
(Shindler et al., 2010). Nicotinamide monucleotide is directly
synthesized into NAD by nicotinamidemononucleotide adenylyl-
transferase (Nmnat), an essential enzyme that catalyzes the final
step of NAD biosynthesis. Several studies demonstrated protec-
tive roles of Nmnat isoforms in axonal degeneration. Nmnat3,
located in mitochondria, can prevent axonal degeneration trig-
gered by ROS in dorsal root ganglia culture (Press and Milbrandt,
2008). It was shown that exogenous Nmnat2, located in the
cytosol, only confers significant protection on cut neurites when
expressed at high levels and endogenous Nmnat2 is essential for
the maintenance of healthy axons (Gilley and Coleman, 2010).
Although the protective role of Nmnat1 remains to be elucidated
(Araki et al., 2004; Conforti et al., 2007), it may confer axonal pro-
tection when it is present not only in the nucleus but also in the
cytoplasm (Yahata et al., 2009). It is possible that Nmnat1 plays
a substantial role in optic nerve axonal degeneration since we
observed that Nmnat1 is present in optic nerve axons and RGC
bodies, and a decline in Nmnat1 precedes axonal degeneration
(Kitaoka et al., 2009). However, this finding may be dependent on
the type of injury or on the neuronal cell type because endoge-
nous Nmnat1 does not have a primary role in axon maintenance
in sciatic nerves and superior cervical ganglia (Conforti et al.,
2011).
Trx AND AXONAL PROTECTION
Trx has two isoforms, Trx1 and Trx2, located in the cytosol
and mitochondria, respectively. Trx1 can be transported antero-
gradely by axoplasmic transport in the sciatic nerve (Stemme
et al., 1985). It was suggested that Trx1 is required for the neu-
rite outgrowth of PC12 cells induced by nerve growth factor (Bai
et al., 2003). In addition, it was suggested that the continued syn-
thesis of Trx1 protein by nerve cells themselves and the secretion
of Trx1 from nerve cells may help to protect cells via an antioxida-
tive role (Lippoldt et al., 1995). In the optic nerve, Trx1 is present
in the axoplasm and colocalized with neurofilament in both the
unmyelinated and myelinated areas (Figures 1A and B). Trx1
is not colocalized with vimentin-positive astrocytes (Figure 1C).
Our previous study demonstrated that a decrease in Trx1 protein
levels in the optic nerve may precede axonal loss and that Trx1
induction may participate in 17β-estradiol-mediated axonal pro-
tection (Kitaoka et al., 2011). It was reported that 17β-estradiol
increased the expression of Trx1 through the cGMP and protein
kinase G signaling pathway in neuronal cells (Lee et al., 2003). In
addition, Trx1 synthesis may be involved in axonal regeneration,
and its inhibition is associated with reduced neurite outgrowth
of dorsal root ganglia neurons (Tonge et al., 2008). Both Trx1
and Trx2 may participate in axonal protection. In a hyperten-
sive glaucoma rat model, a significant decrease in Trx2 levels was
observed in the mitochondrial fraction of the optic nerve com-
pared with control optic nerves (Munemasa et al., 2010). AIF is
FIGURE 1 | Localization of Trx1 in the optic nerve. (A) and (B) Double
staining for Trx1 (green) and neurofilament (red). Substantial co-localization
of Trx1 and NF is observed in the PBS-treated optic nerve. (C) Double
staining for trx1 (green) and vimentin (red). No colocalization of Trx1 and
Vimentin is observed in the PBS-treated optic nerve. Scale bar, 25μm. Trx1,
trioredoxin1; NF, neurofilament.
a phylogenetically conserved redox-active flavoprotein that con-
tributes to cell death and oxidative phosphorylation (Susin et al.,
1999). AIF is activated by its translocation to the cytoplasm and
nucleus under various stresses due to an increase in mitochon-
drial membrane permeability. The inhibition of AIF translocation
by Trx2 overexpression has cytoprotective effects against oxida-
tive stress-induced neurotoxicity by decreasing the mitochon-
drial membrane permeability. Our previous data showed that
increased Trx2 in the optic nerve inhibited AIF translocation from
the mitochondria to axoplasm, thereby leading to axonal protec-
tion against optic nerve degeneration in a hypertensive glaucoma
model (Munemasa et al., 2010). Although apoptosis may occur in
RGC bodies, local axonal AIF translocation from the mitochon-
dria to axoplasmmay play a crucial role in axonal degeneration in
glaucoma.
FUTURE DIRECTIONS
The molecular mechanism of RGC death has been inves-
tigated in several laboratories. However, the molecular
mechanism of local axonal degeneration in glaucoma has
not been elucidated thoroughly. Our laboratory is addressing
this mechanism, and its clarification may be important for
developing neuroprotective agents (Figure 2). Recent imag-
ing techniques allow us to see RGC bodies and the NFL in
glaucoma patients. A very recent study has demonstrated that
adaptive optic scanning laser ophthalmoscopy can visualize
and assess the surface-level pores of the lamina cribrosa in
patients with glaucoma (Akagi et al., 2012). Therefore, it will
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FIGURE 2 | Multiple pathogenic and biological mechanisms for
glaucomatous neurodegeneration. Increased IOP induces several
molecular changes, such as glial activation and release of TNF, mitochondrial
dysfunction, degradation of Trx1, NAD, and nmnat1, and obstruction
ofBDNFtransportat laminaarea.Molecularchanges in theaxoncausedeath
signal activation in RGC body, including release of ROS from mitochondria,
autoimmune dysregulation, and avtivation of glutamate transporter.
TNF, Tumor Necrosis Factor; Trx1, thioredoxin1; NAD, nicotinamide adenine
dinucleotide; BDNF, Brain-derived neurotrophic factor; NMDAR,
N-methyl-D-aspartate receptor; ER, endoplasmic reticulum.
feasible to examine individual axons and cell bodies in glaucoma
patients in the near future. In addition to the reduction of IOP,
the concept of axonal protection may become a new therapeutic
strategy to prevent further axonal degeneration or revive dying
axons in patients with preperimetric glaucoma. Further study will
be needed to clarify whether the combination therapy of axonal
protection and cell body protection will have greater protective
effects in early or progressive GON.
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